Article
Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jan 2026
Pineda-Lopez Lina, Aguillon David, Villar-Vesga Juan, Valderrama-Carmona Pablo, Guerrero Alejandro, Upreti Anil, Arevalo-Alquichire Said, Correa Laura, Mendez-Castellanos Karin, Castaño Diana, Cardona-Gomez Gloria P, Fernandez Geysson J, Kim Leo A, Arboleda-Velasquez Joseph F, Posada-Duque Rafael
Abstract excerpt
INTRODUCTION: The PSEN1E280A mutation causes autosomal dominant Alzheimer's disease (ADAD) with predictable onset, enabling presymptomatic studies. Extracellular vesicles (EVs) are emerging biomarkers of cognitive decline, but their role in early ADAD is unclear. The rare apolipoprotein E (APOE3) Christchurch (APOE3Ch) variant delays disease onset, yet its effect on EVs is unknown. METHODS: We analyzed plasma EVs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
